Publication
Wavelength-Specific UV-C Inactivation of Viruses in Liquids: Dose-Response, Mechanistic Insights, and Structural Integrity
Hetényi R, Hanna D, et al. Viruses 2026, 18(3), 276. Systematic review and meta-analysis.
Pandemic Preparedness Platform
ART OF
THE KILL
Rapid-response UV inactivation for pandemic preparedness.
RoLink Biotechnology develops UV-based viral inactivation platforms enabling safer diagnostics, vaccine development, and biodefense applications while preserving viral structure.
Scroll
The Global Challenge
Only 51 BSL-4 facilities exist worldwide.
High-containment virology research is expensive, operationally restrictive, and inaccessible to most institutions. Dangerous pathogens require BSL-3/BSL-4 infrastructure that fewer than 1% of laboratories can provide — creating a critical bottleneck in pandemic preparedness, vaccine development, and biodefense research.
10,000+
BSL-2
Standard labs
~1,500
BSL-3
Enhanced containment
51
BSL-4
Maximum containment
RoLink eliminates this bottleneck
UV Inactivation Platform
How It Works
Biosafety Infrastructure
The Painful Bottleneck
High-containment laboratory research is expensive, operationally restrictive, infrastructure-limited, and inaccessible to most institutions worldwide. RoLink technology enables safer downstream workflows beyond traditional biosafety bottlenecks.
BSL-2RoLink Enabled
~10,000+ facilitiesStandard laboratory equipment. Influenza, Zika, Hepatitis B.
BSL-3
~1,500 facilitiesEnhanced containment, HEPA filtration. SARS-CoV-2, mpox, West Nile.
BSL-4
51 facilitiesFull positive-pressure suits. Ebola, Marburg, Nipah, CCHFV.
"BSL-4 operators are rarer than astronauts — RoLink makes downstream applications available and scalable."
BSL-2RoLink Enabled
BSL-3
BSL-4
Quantitative Scientific Proof
Scientific Validation
Evidence-Based Results
RoLink technology has been validated through internal research and independent laboratory collaborations, demonstrating that UV inactivation preserves critical viral structures while enabling safer downstream applications compared to traditional chemical methods.
Comparison of Inactivation Technologies for Vaccine Production
Chemical inactivation vs UV inactivation
Feature
Chemical Inactivation
UV Inactivation
Production Speed
Days to weeks
Potentially within one day
Purification Integration
Separate step required
Can integrate into workflow
Production Cost
Higher chemical & handling costs
May reduce overall costs
Shelf Life
Standard
May support longer shelf life
Manufacturing
Batch processing
Compatible with continuous-flow
Immune Response
Mainly IgG1-dominant antibodies
Broader: T-cell + antibody responses
Fig. 1|Comparison of chemical and UV-based inactivation approaches for vaccine production workflows.
Scientific Interpretation
UV inactivation offers potential advantages over traditional chemical methods across multiple production parameters. Key differences include faster processing times (potentially within one day vs days to weeks), compatibility with continuous-flow manufacturing, and the ability to integrate purification directly into the production workflow.
Importantly, UV-inactivated vaccines may support broader immune activation including both T-cell and antibody responses, whereas chemically inactivated vaccines tend to primarily induce IgG1-dominant antibody responses. These characteristics may contribute to improved vaccine efficacy and broader protective immunity.
Applications
Platform Applications
Accelerated Vaccine Candidate Development
Diagnostics
Biodefense
Pandemic Preparedness
Faster Vaccine and Assay Development
Opening High-Containment Research to BSL-2 Laboratories
BSL-4 Laboratories in Europe
University of Pécs — National Laboratory of Virology
Pécs, Hungary
PTE VNL / SZKK
BSL-4 Laboratory
RoLink / PTE VNL
Source: thebulletin.org/global-biolabs
Located in Pécs, Hungary, within the University of Pécs Szentágothai Research Centre (SZKK), the National Laboratory of Virology (PTE VNL) operates Central and Eastern Europe's only university-affiliated BSL-4 research laboratory dedicated to research purposes.
Traction & Milestones
Validated Progress
Institutional backing, peer-reviewed validation, and strategic partnerships demonstrate RoLink's translational readiness.
2
Patents Filed
PCT/HU2025/050010 + 1 pending
3
Peer-Reviewed Publications
Viruses, Vaccines (MDPI)
6
Institutional Partners
Defense, academic, veterinary
3+
Validated Virus Models
SARS-CoV-2, Sindbis, Zika
€1M+
Grants Secured
Combined grant and institutional project funding.
1
BSL-4 Partnership
University of Pécs NLV
Team & Board
Scientific Team
Dr. Roland Hetényi
CEO, Medical Doctor
Virology, UV Inactivation Technology, Biosafety
Medical doctor and pioneer in UV-based virus inactivation. Founded RoLink to bridge the gap between high-containment virology and scalable biodefense. Secured 350,000 EUR COVID Fund grant and leads IP development (PCT/HU2025/050010).
LinkedIn
Dr. Dániel Hanna
Co-owner, Medical Doctor
Vaccine Development, Purification, Biodefense
Medical doctor specializing in vaccine development and virus purification. Co-developed RoLink's proprietary anion exchange chromatography method achieving 75.5% RNA recovery rates.
Péter Szabó
Researcher
Scientific Writing, Systematic Reviews, Meta-Analysis
Specializes in scientific writing, systematic reviews, meta-analysis, and biosafety-focused biomedical research. His work focuses on evidence synthesis, scientific communication, and translational research strategy.
LinkedIn
Zoltán Kopasz
Researcher
Virology, Antivirals, Inactivation Specialist
Biologist working in virology, antiviral research, and viral inactivation technologies, with a particular interest in Zika virus research and emerging viral pathogens.
LinkedIn
Gréta Varga
Researcher
Virology, Industrial Biotechnology, Hantavirus
Biotechnology researcher specializing in virology and applied industrial biotechnology. Her work focuses on hantavirus isolation and characterization, viral inactivation technologies, antiviral research, and the development of innovative validation systems supporting next-generation biotechnological products.
Advisory Board
dr. Tibor Héjj
Board Member
Innovation Management, IP Strategy
Experienced innovation strategist with deep expertise in intellectual property management, technology transfer, and strategic advisory for deep-tech ventures in the life sciences sector.
LinkedIn
dr. János Matuz
Board Member
Regulatory Strategy
Senior advisor with extensive experience in biodefense policy, biosafety regulatory frameworks, and institutional governance for biotechnology organizations operating within national security and public health domains.
Balázs Antal Somogyi
Chief Biosafety Advisor
Biosafety, Epidemic Preparedness, Strategic Collaboration
Serves as Chief Biosafety Advisor for RoLink Biotechnology's pandemic defense development project focused on UV inactivation technologies. With expertise in biosafety, epidemic preparedness, and strategic scientific collaboration, he supports the project through professional advisory work, international networking, and the development of research and industrial partnerships.
LinkedIn
Dr. Gábor Kemenesi
Senior Advisor & Virologist
Emerging Viruses, Zoonotic Transmission, Pandemic Preparedness
Dr. Gábor Kemenesi serves as mentor and scientific advisor to RoLink Biotechnology Kft. within the framework of the NKFIH-funded project "Védelmi képességfejlesztés a járványok korában: UV-inaktiváció" (Project ID: 2023-1.1.2-GYORSÍTÓSÁV-2024-00020). As a member of the National Innovation Agency's (NIÜ) Mentor Program, he provides expert support in virology, contributing to the successful implementation of the project and its scientific and innovation objectives. In his mentoring role, Dr. Kemenesi provides ongoing scientific consultation, strategic guidance, and professional support to the RoLink team throughout the project period. His expertise strengthens the company's research and development activities related to UV-based viral inactivation technologies and pandemic preparedness solutions.
LinkedInInvestment Opportunity
Building Scalable Biodefense Infrastructure
RoLink is positioned at the intersection of a $21.5B CBRN market, institutional defense mandates, and a validated technology platform with clear regulatory and commercialization pathways.
Market Opportunity
The global CBRN defense market is valued at $21.5B (2024) with European Defence Fund allocating €1B+ in 2025 calls. UV inactivation technology addresses a validated unmet need across defense, public health, and veterinary sectors.
IP & Competitive Position
Protected by PCT/HU2025/050010 with additional patents pending. RoLink's proprietary UV-C calibration preserves both protein and RNA integrity — a differentiation no chemical inactivation method achieves.
Technology Readiness
TRL 4–5 with validated preclinical data (ELISA, qPCR, animal models). Clear pathway to GMP-scale production through closed-system bioreactor integration currently in development.
Business Model
Technology licensing to pharmaceutical, veterinary, and defense partners. Service contracts for institutional virus inactivation. Co-development agreements for vaccine candidate programs.
News & Publications
Latest Updates
Publication
Sindbis Virus–Host Interactions in Human Neuroblastoma Cells
Bodó K, ... Hetényi R, Hanna D, et al. Viruses 2025, 17(10), 1346.
Publication
Evaluating the Protective Role of Intranasally Administered Avian-Derived IgY Against SARS-CoV-2
Madai M, Hanna D, Hetényi R, et al. Vaccines 2024, 12(12), 1422.
Partnership
RoLink Secures Partnership with National Laboratory of Virology
Strategic collaboration with University of Pécs BSL-4 facility.
Biodefense
EDF Integration Framework Announced
RoLink technology integrated into European Defence Fund pandemic response protocols.
Get In Touch
Let's build the future of pandemic resilience together.
Whether you're a government agency, research institution, defense organization, or biotech partner, we'd like to hear from you.
RoLink Biotechnology Research and Development Kft.
7624 Pécs, Ifjúság útja 20., Hungary
info@rolinkbiotechnology.com